Literature DB >> 19182202

Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden.

Ola Landgren1, Sigurdur Y Kristinsson, Lynn R Goldin, Neil E Caporaso, Cecilie Blimark, Ulf-Henrik Mellqvist, Anders Wahlin, Magnus Bjorkholm, Ingemar Turesson.   

Abstract

Familial clustering of the precursor condition, monoclonal gammopathy of undetermined significance (MGUS) has been observed in case reports and in smaller studies. Using population-based data from Sweden, we identified 4458 MGUS patients, 17505 population-based controls, and first-degree relatives of patients (n = 14621) and controls (n = 58387) with the aim to assess risk of MGUS and lymphoproliferative malignancies among first-degree relatives of MGUS patients. Compared with relatives of controls, relatives of MGUS patients had increased risk of MGUS (relative risk [RR] = 2.8; 1.4-5.6), multiple myeloma (MM; RR = 2.9; 1.9-4.3), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM; RR = 4.0; 1.5-11), and chronic lymphocytic leukemia (CLL; RR = 2.0; 1.2-2.3). Relatives of patients with IgG/IgA MGUS had a 4.0-fold (1.7-9.2), 2.9-fold (1.7-4.9), and 20-fold (2.3-170) elevated risk of developing MGUS, MM, and LPL/WM, respectively. Relatives of IgM MGUS patients had 5.0-fold (1.1-23) increased CLL risk and nonsignificant excess MM and LPL/WM risks. The results were very similar when we assessed risk by type of first-degree relative, age at MGUS (above/below 65 years), or sex. Risk of non-Hodgkin lymphoma or Hodgkin lymphoma was not increased among MGUS relatives. Among first-degree relatives of a nationwide MGUS cohort, we found elevated risks of MGUS, MM, LPL/WM, and CLL, supporting a role for germline susceptibility genes, shared environmental influences, or an interaction between both.

Entities:  

Mesh:

Year:  2009        PMID: 19182202      PMCID: PMC2716021          DOI: 10.1182/blood-2008-12-191676

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Methods for testing familial aggregation of diseases in population-based samples: application to Hodgkin lymphoma in Swedish registry data.

Authors:  R M Pfeiffer; L R Goldin; N Chatterjee; S Daugherty; K Hemminki; D Pee; L I X; M H Gail
Journal:  Ann Hum Genet       Date:  2004-09       Impact factor: 1.670

2.  Monoclonal proteins in chronic lymphocytic leukemia.

Authors:  P Noel; R A Kyle
Journal:  Am J Clin Pathol       Date:  1987-03       Impact factor: 2.493

3.  Familial occurrence of multiple myeloma and monoclonal gammopathy of undetermined significance in 5 siblings.

Authors:  N Bizzaro; P Pasini
Journal:  Haematologica       Date:  1990 Jan-Feb       Impact factor: 9.941

4.  Frequency of pathological proteins (M-components) om 6,995 sera from an adult population.

Authors:  U Axelsson; R Bachmann; J Hällén
Journal:  Acta Med Scand       Date:  1966-02

Review 5.  Familial multiple myeloma: a family study and review of the literature.

Authors:  H T Lynch; W G Sanger; S Pirruccello; B Quinn-Laquer; D D Weisenburger
Journal:  J Natl Cancer Inst       Date:  2001-10-03       Impact factor: 13.506

6.  Familial aggregation of Hodgkin lymphoma and related tumors.

Authors:  Lynn R Goldin; Ruth M Pfeiffer; Gloria Gridley; Mitchell H Gail; Xinjun Li; Lene Mellemkjaer; Jørgen H Olsen; Kari Hemminki; Martha S Linet
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

7.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

8.  Long-term follow-up of IgM monoclonal gammopathy of undetermined significance.

Authors:  Robert A Kyle; Terry M Therneau; S Vincent Rajkumar; Ellen D Remstein; Janice R Offord; Dirk R Larson; Matthew F Plevak; L Joseph Melton
Journal:  Blood       Date:  2003-07-24       Impact factor: 22.113

9.  Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.

Authors: 
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

10.  Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions.

Authors:  Roelandt F J Schop; W Michael Kuehl; Scott A Van Wier; Gregory J Ahmann; Tammy Price-Troska; Richard J Bailey; Syed M Jalal; Ying Qi; Robert A Kyle; Philip R Greipp; Rafael Fonseca
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

View more
  62 in total

1.  Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women.

Authors:  Ola Landgren; S Vincent Rajkumar; Ruth M Pfeiffer; Robert A Kyle; Jerry A Katzmann; Angela Dispenzieri; Qiuyin Cai; Lynn R Goldin; Neil E Caporaso; Joseph F Fraumeni; William J Blot; Lisa B Signorello
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

2.  Familial Aspects of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and Related Lymphomas.

Authors:  Lynn R Goldin; Ola Landgren; Gerald E Marti; Neil E Caporaso
Journal:  European J Clin Med Oncol       Date:  2010-02

Review 3.  Inherited genetic susceptibility to multiple myeloma.

Authors:  G J Morgan; D C Johnson; N Weinhold; H Goldschmidt; O Landgren; H T Lynch; K Hemminki; R S Houlston
Journal:  Leukemia       Date:  2013-11-19       Impact factor: 11.528

4.  Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-06-22       Impact factor: 9.941

Review 5.  Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies.

Authors:  Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Jill Koshiol; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941

6.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

7.  Identification of key genes and construction of microRNA-mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis.

Authors:  Hongyu Gao; Huihan Wang; Wei Yang
Journal:  Int J Hematol       Date:  2017-03-18       Impact factor: 2.490

Review 8.  Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.

Authors:  Sigurdur Yngvi Kristinsson; Ola Landgren; Vincent S Rajkumar
Journal:  Cancer J       Date:  2009 Nov-Dec       Impact factor: 3.360

9.  Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study.

Authors:  Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

10.  Recent advances in bone marrow biopsy pathology.

Authors:  Jon van der Walt
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.